Mill Creek Capital Advisors LLC Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Mill Creek Capital Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 8.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,498 shares of the company’s stock after purchasing an additional 194 shares during the quarter. Mill Creek Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $2,262,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Core Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $37,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 425,000 shares of company stock worth $394,455,351 in the last quarter. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $919.36 on Tuesday. The business has a 50 day moving average price of $894.44 and a 200 day moving average price of $839.71. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market cap of $873.76 billion, a price-to-earnings ratio of 135.40, a PEG ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Equities research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Barclays boosted their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Citigroup assumed coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective for the company. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.